Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

August 05, 2025 at 09:05 AM EDT

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company
Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement
CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl”

Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug’s safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable risks reach patients. Recognizing the immense value this milestone represents, Nutriband (NASDAQ: NTRB) recently underscored its commitment to this pathway by announcing a 25% preferred stock dividend as the company targets filing for FDA approval for its lead product, AVERSA(TM) Fentanyl (https://ibn.fm/8FRUA).

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company. Recent research published in “Drug Discovery Today” examined biotech firms that received FDA Fast Track designation between 2019 and 2020 and found average cumulative abnormal returns (“CAR”) of…

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

About Us

Additional Information

Website & Technical Help

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

More News